Breast Cancer
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its prior HER2-low indication.
Read More
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.
Listen
T-DXd Reevaluated in HER2-Low/HER2-Negative Breast Cancer After New Trials
During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast cancer and the need for HER2-negative data with T-DXd.
Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
A Real-Time Cancer-Detecting System for Breast Cancer Goes Live
The LumiSystem detection tool is now commercially available in the US.
Expert Explores the Optimal Approach of Radiation Therapy and Breast Reconstruction During Breast Cancer Conference
The use of radiation therapy has become a staple in breast cancer treatment, with benefits seen in node-positive patients, those with locally advanced disease, and those with large-sized tumors.
